The overall objective is to develop a new Syrian Hamster Embryo (SHE) Morphological Transformation Assay (MTA) employing specific cell types as targets and using defined, serum-free culture media. Specific aims for Phase I study include:(1) isolation and characterization of specific cell types (chondrocytes, mycocytes, fibroblasts, endothelial cells) from SHE as targets for the in vitro transformation assay;(2) adaptation of each of the selected target cell types to grow in appropriate serum-free growth media;(3) development of a prototype serum-free medium that enhances the transformed phenotype.Technical innovation in this project lies in the substitution of defined factors in place of serum and avoiding the use of X-irradiated "feeder" cells in the assay. Identification of specific types of cells that might represent preferred targets for particular carcinogens would constitute an important improvement over current MTAS. Procedures and reagents developed will be useful in screening environmental chemicals for their carcinogenic potential, hence will be commercially valuable.Awardee's statement of the potential commercial applications of the research:This new, reproducible Morphological Transformation Assay will be used extensively for screening carcinogenic and toxic potential of chemicals. We will provide this new assay as a service to the pharmaceutical and chemical industries and to government agencies such as NCI, NIEHS and EPA.National Institute of Environmental Health Sciences (NIEHS)
